Tags : RNAi Therapies

Novo Nordisk Collaborates with Dicerna to Discover and Develop RNAi

Shots: Dicerna to receive $175M up front, $50M equity investment, $75M for first three years of collaboration and up to $375.5M/ target as development, regulatory and commercialization milestones with royalties on product sales Both the companies will retain rights to co-develop and co-commercialize candidates and will explore up to 30 liver cell targets for which […]Read More

Théa and OliX Announce Collaboration to Develop RNAi Therapies for

Shots: OliX to receive $2.27M upfront, clinical milestones and royalties on sales of product. Thea to get license rights to develop & commercialize OLX301A in EU, Middle East and Africa (Ex- the US & Asia) The focus of the agreement is to develop therapies based on OliX’s RNAi technology with the expansion of Thea’s Ophthalmology […]Read More